These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 15979942)

  • 1. Antigen-specific CD8+ T lymphocytes generated from a DNA vaccine control tumors through the Fas-FasL pathway.
    Cheng WF; Lee CN; Chang MC; Su YN; Chen CA; Hsieh CY
    Mol Ther; 2005 Nov; 12(5):960-8. PubMed ID: 15979942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination.
    Cheng WF; Hung CF; Lin KY; Ling M; Juang J; He L; Lin CT; Wu TC
    Gene Ther; 2003 Aug; 10(16):1311-20. PubMed ID: 12883527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways.
    Cheng WF; Hung CF; Lee CN; Su YN; Chang MC; He L; Wu TC; Chen CA; Hsieh CY
    Eur J Immunol; 2004 Jul; 34(7):1892-900. PubMed ID: 15214037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of HPV DNA vaccines employing intracellular targeting strategies.
    Kim JW; Hung CF; Juang J; He L; Kim TW; Armstrong DK; Pai SI; Chen PJ; Lin CT; Boyd DA; Wu TC
    Gene Ther; 2004 Jun; 11(12):1011-8. PubMed ID: 14985791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens.
    Huang CY; Chen CA; Lee CN; Chang MC; Su YN; Lin YC; Hsieh CY; Cheng WF
    Gynecol Oncol; 2007 Dec; 107(3):404-12. PubMed ID: 17905417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin.
    Hsieh CJ; Kim TW; Hung CF; Juang J; Moniz M; Boyd DA; He L; Chen PJ; Chen CH; Wu TC
    Vaccine; 2004 Sep; 22(29-30):3993-4001. PubMed ID: 15364449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen.
    Cheng WF; Hung CF; Chai CY; Hsu KF; He L; Ling M; Wu TC
    J Clin Invest; 2001 Sep; 108(5):669-78. PubMed ID: 11544272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity.
    Cheng WF; Lee CN; Su YN; Chai CY; Chang MC; Polo JM; Hung CF; Wu TC; Hsieh CY; Chen CA
    Cancer Gene Ther; 2006 Sep; 13(9):873-85. PubMed ID: 16645621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
    Ryan AE; Shanahan F; O'Connell J; Houston AM
    Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noncarrier naked antigen-specific DNA vaccine generates potent antigen-specific immunologic responses and antitumor effects.
    Chen CA; Chang MC; Sun WZ; Chen YL; Chiang YC; Hsieh CY; Chen SM; Hsiao PN; Cheng WF
    Gene Ther; 2009 Jun; 16(6):776-87. PubMed ID: 19357714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Jayaprabhu S; Pecorelli S; Parham GP; Cannon MJ
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):804s-810s. PubMed ID: 11300476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene.
    Chen CH; Wang TL; Ji H; Hung CF; Pardoll DM; Cheng WF; Ling M; Wu TC
    Gene Ther; 2001 Jan; 8(2):128-38. PubMed ID: 11313782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs.
    Chen CH; Ji H; Suh KW; Choti MA; Pardoll DM; Wu TC
    Gene Ther; 1999 Dec; 6(12):1972-81. PubMed ID: 10637448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of DNA vaccine potency through linkage of antigen gene to ER chaperone molecules, ER-60, tapasin, and calnexin.
    Lin CT; Chang TC; Chao A; Dzeng E; Soong YK; Hung CF; Lai CH
    J Biomed Sci; 2005; 12(2):279-87. PubMed ID: 15918000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies.
    Peng S; Trimble C; Ji H; He L; Tsai YC; Macaes B; Hung CF; Wu TC
    J Biomed Sci; 2005 Oct; 12(5):689-700. PubMed ID: 16200349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Photodynamic therapy-generated tumor cell lysates with CpG-oligodeoxynucleotide enhance immunotherapy efficacy in human papillomavirus 16 (E6/E7) immortalized tumor cells.
    Bae SM; Kim YW; Kwak SY; Kim YW; Ro DY; Shin JC; Park CH; Han SJ; Oh CH; Kim CK; Ahn WS
    Cancer Sci; 2007 May; 98(5):747-52. PubMed ID: 17425690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
    Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy.
    Bae SH; Park YJ; Park JB; Choi YS; Kim MS; Sin JI
    Clin Cancer Res; 2007 Jan; 13(1):341-9. PubMed ID: 17200373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
    Matsumoto K; Leggatt GR; Zhong J; Liu X; de Kluyver RL; Peters T; Fernando GJ; Liem A; Lambert PF; Frazer IH
    J Natl Cancer Inst; 2004 Nov; 96(21):1611-9. PubMed ID: 15523090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.